-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Reviewing Bone Biologics (OTC:BBLG) & Sientra (NASDAQ:SIEN)
Reviewing Bone Biologics (OTC:BBLG) & Sientra (NASDAQ:SIEN)
Bone Biologics (OTC:BBLG – Get Rating) and Sientra (NASDAQ:SIEN – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.
Profitability
This table compares Bone Biologics and Sientra's net margins, return on equity and return on assets.
Get Bone Biologics alerts:Net Margins | Return on Equity | Return on Assets | |
Bone Biologics | N/A | 7,587.33% | 7,258.20% |
Sientra | -76.47% | -381.27% | -36.56% |
Insider & Institutional Ownership
0.5% of Bone Biologics shares are owned by institutional investors. Comparatively, 68.4% of Sientra shares are owned by institutional investors. 1.3% of Sientra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Bone Biologics and Sientra's revenue, earnings per share and valuation.Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Bone Biologics | N/A | N/A | -$1.61 million | N/A | N/A |
Sientra | $80.68 million | 0.31 | -$62.48 million | ($1.09) | -0.23 |
Bone Biologics has higher earnings, but lower revenue than Sientra.
Analyst Recommendations
This is a summary of current ratings and target prices for Bone Biologics and Sientra, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
Sientra | 0 | 1 | 6 | 0 | 2.86 |
Bone Biologics currently has a consensus target price of $2.25, indicating a potential upside of 837.50%. Sientra has a consensus target price of $5.19, indicating a potential upside of 2,010.59%. Given Sientra's higher probable upside, analysts clearly believe Sientra is more favorable than Bone Biologics.
Risk and Volatility
Bone Biologics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Sientra has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Summary
Sientra beats Bone Biologics on 6 of the 11 factors compared between the two stocks.
About Bone Biologics
(Get Rating)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
About Sientra
(Get Rating)
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
Bone Biologics (OTC:BBLG – Get Rating) and Sientra (NASDAQ:SIEN – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.
骨生物(场外交易:BBLG-GET评级)和西恩特拉(纳斯达克:SEN-GET评级)都是小盘医疗公司,但哪一家更好?我们将根据这两家公司的盈利能力、估值、风险、收益、股息、分析师建议和机构所有权的强项对其进行比较。
Profitability
盈利能力
This table compares Bone Biologics and Sientra's net margins, return on equity and return on assets.
该表比较了骨生物和西恩特拉的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Bone Biologics | N/A | 7,587.33% | 7,258.20% |
Sientra | -76.47% | -381.27% | -36.56% |
净利润率 | 股本回报率 | 资产回报率 | |
骨生物制品 | 不适用 | 7,587.33% | 7,258.20% |
西恩特拉 | -76.47% | -381.27% | -36.56% |
Insider & Institutional Ownership
内部人与机构所有权
0.5% of Bone Biologics shares are owned by institutional investors. Comparatively, 68.4% of Sientra shares are owned by institutional investors. 1.3% of Sientra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
骨生物公司0.5%的股份由机构投资者持有。相比之下,Sientra 68.4%的股份由机构投资者持有。Sientra 1.3%的股份由内部人士持有。强大的机构持股表明,捐赠基金、大型基金管理公司和对冲基金相信,一只股票有望实现长期增长。
Earnings & Valuation
收益与估值
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Bone Biologics | N/A | N/A | -$1.61 million | N/A | N/A |
Sientra | $80.68 million | 0.31 | -$62.48 million | ($1.09) | -0.23 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
骨生物制品 | 不适用 | 不适用 | -161万美元 | 不适用 | 不适用 |
西恩特拉 | 8,068万美元 | 0.31 | -6,248万元 | ($1.09) | -0.23 |
Bone Biologics has higher earnings, but lower revenue than Sientra.
Bbone Biologics的收益比Sientra高,但收入比Sientra低。
Analyst Recommendations
分析师建议
This is a summary of current ratings and target prices for Bone Biologics and Sientra, as reported by MarketBeat.
这是MarketBeat报道的骨生物制品和Sientra的当前评级和目标价格的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
Sientra | 0 | 1 | 6 | 0 | 2.86 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
骨生物制品 | 0 | 0 | 1 | 0 | 3.00 |
西恩特拉 | 0 | 1 | 6 | 0 | 2.86 |
Bone Biologics currently has a consensus target price of $2.25, indicating a potential upside of 837.50%. Sientra has a consensus target price of $5.19, indicating a potential upside of 2,010.59%. Given Sientra's higher probable upside, analysts clearly believe Sientra is more favorable than Bone Biologics.
Bbone Biologics目前的共识目标价为2.25美元,表明潜在上行空间为837.50%。Sientra的共识目标价为5.19美元,表明潜在涨幅为2,010.59%。考虑到Sientra更有可能的上行空间,分析师们显然认为Sientra比骨生物制药更有利。
Risk and Volatility
风险和波动性
Bone Biologics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Sientra has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Bone Biologics的贝塔系数为0.11,这表明其股价的波动性比标准普尔500指数低89%。相比之下,Sientra的贝塔系数为1.51,这表明其股价的波动性比标准普尔500指数高出51%。
Summary
摘要
Sientra beats Bone Biologics on 6 of the 11 factors compared between the two stocks.
在两只股票比较的11个因素中,Sientra有6个击败了bone Biologics。
About Bone Biologics
关于骨生物制品
(Get Rating)
(获取评级)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
骨生物公司是一家医疗设备公司,专注于使用重组人蛋白在脊柱融合中进行骨再生。该公司的Nell-1/DBX是一种组合产品,是一种骨刺激重组蛋白,提供对骨再生的靶向特异性控制。该公司正在开发Nell-1/DBX融合器,用于L4-S1一级退行性腰椎间盘疾病骨性成熟患者的脊柱融合手术。该公司的平台技术在脊柱、整形外科、普通整形外科、整形外科、神经外科、介入放射学和运动医学等外科专业中具有增强的应用效果。它与加州大学洛杉矶分校技术开发集团签署了一项许可协议,开发和商业化用于脊柱融合应用的Nell-1。该公司成立于2004年,总部设在马萨诸塞州伯灵顿。
About Sientra
关于Sientra
(Get Rating)
(获取评级)
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Sientra,Inc.是一家医学美学公司,在美国和国际上开发和销售医学美学产品。该公司提供用于隆胸和乳房再造手术的硅胶乳房植入物;乳房组织扩张器;以及Sientra圆形、Sientra TearDrop、allX2、Dermaspan、SoftSpan和BIOCORNEUM品牌的疤痕处理产品。该公司还提供身体塑形产品;面部和鼻部植入物;生理盐水填充的尺码。它为医院、外科中心、整形外科医生、皮肤科医生和其他专科医生提供服务。该公司前身为Juliet Medical,Inc.,并于2007年4月更名为Sientra,Inc.。Sientra,Inc.成立于2003年,总部设在加利福尼亚州圣巴巴拉。
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
接受骨生物制品日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收骨生物和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧